Search Results

The Helicobacter pylori (H. pylori) ELISA IgA test kit is intended for the qualitative detection of IgA antibodies to H. pylori in human serum in the adult population. This test is intended as a second test to aid in the diagnosis of H. pylori in patients with gastrointestinal symptoms, in conjunction with clinical findings. It should be performed and interpreted with another assay for detection of IgG antibodies to H. pylori.

The assay requires a total of 90 minutes incubation time. The test uses purified antigen coated on microtiter wells. Serum is added to each well and incubated for 30 minutes at 37°C. If H. pylori IgA antibodies are present they will bind to the antigen in the well. Unbound serum is removed by washing the wells three times. An HRP-conjugated anti-human IgA is then added to each well and incubated for 30 minutes at 37°C. If H. pylori antibody is present, it will bind to the antibody attached to the antigen on the wells are again washed three times to remove any unbound conjugate. A TMB substrate is added to each well and incubated for 30 minutes at 37°C. If enzyme is present, it will react with the substrate to generate a colored product. After the incubation period, Stop Solution and the color intensity is measured the reaction is stopped with a spectrophotometrically.

The document describes the Gold Standard Diagnostics Helicobacter pylori IgA ELISA Test Kit and its performance characteristics.

1. Table of Acceptance Criteria and Reported Device Performance

The provided document doesn't explicitly state "acceptance criteria" through a formal table. However, the study focuses on demonstrating substantial equivalence to a predicate device, and the key performance metrics reported are Percent Positive Agreement, Percent Negative Agreement, and Overall Agreement with the predicate device (Micro Detect Inc. Pylori Detect IgA).

Note: The acceptance criteria for agreement with the predicate are implied by the demonstration of substantial equivalence, rather than explicitly stated numerical targets.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size for Test Set: 625 samples.
• Data Provenance: The samples were "routinely tested for H. pylori," suggesting they were clinical samples. The document does not specify the country of origin, nor explicitly state if they were retrospective or prospective, although "routinely tested" implies existing samples (retrospective).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

This type of information is not applicable to this study. The "ground truth" for the comparative effectiveness study was established by comparing the performance of the new device to a legally marketed predicate device (Micro Detect Inc. Pylori Detect IgA). For discrepant samples, a third commercially available assay (Inova QUANTA Lite™ H. pylori IgA ELISA) was used for adjudication. No human expert interpretation of raw data (e.g., radiologists reading images) was involved in establishing the ground truth for the device's diagnostic performance in the primary comparison.

4. Adjudication Method for the Test Set

For discrepant samples between the Gold Standard Diagnostics H. pylori ELISA IgA assay and the Micro Detect Inc. Pylori Detect IgA assay, a third, commercially available ELISA assay (Inova QUANTA Lite™ H. pylori IgA ELISA) was used. The document does not specify a numerical adjudication rule (e.g., 2+1, 3+1), but rather that the "third assay called" the outcome for these discrepant samples.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was Done

No, a Multi Reader Multi Case (MRMC) comparative effectiveness study was not done. This study evaluates an automated ELISA test kit, not a device requiring human interpretation of results, and therefore, the concept of "human readers" or "AI assistance" in the context of improving human performance is not applicable.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

Yes, a standalone performance efficacy study was done. The device itself is an automated ELISA test kit, which performs its function without continuous human intervention during the assay process to determine a positive or negative result. The clinical comparison and all non-clinical tests (precision, reproducibility, cross-reactivity, interfering substances, limit of detection) evaluate the device's standalone performance.

7. The Type of Ground Truth Used

The primary "ground truth" for the comparative effectiveness study was the result from a legally marketed predicate device (Micro Detect Inc. Pylori Detect IgA). For discrepant results, a third commercially available ELISA assay (Inova QUANTA Lite™ H. pylori IgA ELISA) was used as an adjudicator. This is a form of reference standard test agreement, rather than expert consensus, pathology, or direct outcomes data (like biopsy results).

8. The Sample Size for the Training Set

The document does not specify a sample size for a "training set." This type of information is typically relevant for machine learning-based devices. For an ELISA kit, development and optimization would involve internal studies, but these are not usually referred to as a "training set" in the same way.

9. How the Ground Truth for the Training Set Was Established

As no "training set" is explicitly mentioned for a machine learning context, the method for establishing its ground truth is not applicable/not provided. The development of an ELISA kit relies on established biochemical principles and extensive internal validation and optimization against known positive and negative samples, calibration standards, and various interfering substances to define its operational parameters and cutoff values.

Ask a specific question about this device